中国组织工程研究 ›› 2016, Vol. 20 ›› Issue (50): 7494-7499.doi: 10.3969/j.issn.2095-4344.2016.50.007

• 干细胞移植 stem cell transplantation • 上一篇    下一篇

骨髓间充质干细胞调节心脏移植大鼠的免疫功能

赵  敏,李秀芬   

  1. 郑州澍青医学高等专科学校基础医学部,河南省郑州市  450000
  • 修回日期:2016-10-31 出版日期:2016-12-02 发布日期:2016-12-02
  • 作者简介:赵敏,女,1983年生,河南省郑州市人,汉族,硕士,讲师,主要从事微生物免疫学方面的研究。

Immune function regulation by bone marrow mesenchymal stem cells in rats undergoing heart transplantation

Zhao Min, Li Xiu-fen   

  1. School of Basic Medicine, Shuqing Medical College, Zhengzhou 450000, Henan Province, China
  • Revised:2016-10-31 Online:2016-12-02 Published:2016-12-02
  • About author:Zhao Min, Master, Lecturer, School of Basic Medicine, Shuqing Medical College, Zhengzhou 450000, Henan Province, China

摘要:

文章快速阅读:

文题释义:
白细胞介素10:
是一种多细胞源、多功能的细胞因子,调节细胞的生长与分化,参与炎性反应和免疫反应,是目前公认的炎症与免疫抑制因子。白细胞介素10来源于Th2和部分调节性T细胞,能抑制Th1细胞应答,抑制巨噬细胞的抗原提呈功能及合成细胞因子,促进B细胞增殖、分化及抗体产生。
Foxp3:是控制Treg细胞发育和功能的关键转录因子之一,它的发现是Treg免疫生物学重要的进步。虽然人们也发现Treg发育和功能也需要其他转录因子如AhR和STAT5的参与,但是Foxp3仍旧是Treg细胞系的主要调节因子。实验表明,在体外或体内诱导初始T细胞表达Foxp3后可以出现Treg样的免疫抑制作用,可见Foxp3是控制免疫抑制分子表达的关键因素。

 

摘要
背景:
心脏移植是治疗终末期心力衰竭等疾病的有效手段,但移植后容易出现免疫排斥反应,严重影响到移植效果。
目的:探讨骨髓间充质干细胞对心脏移植大鼠免疫功能的调节作用。
方法:Lewis大鼠20只作为供体,Wistar大鼠20只作为受体,采用套管法建立大鼠颈部心脏移植模型。模型制备后,20只Wistar大鼠随机分为细胞移植组与空白对照组,每组10只。心脏移植后48 h,细胞移植组经尾静脉注射骨髓间充质干细胞悬液1 mL(细胞浓度为2×108 L-1),空白对照组经尾静脉注射等量的生理盐水注射液。细胞移植后7 d,ELISA法检测血清白细胞介素2、白细胞介素10水平,流式细胞术检测大鼠静脉血中CD4+、CD8+、CD4+/CD8+、CD4+CD25high、CD4+CD25high Foxp3+ T细胞百分含量,获取心肌组织进行病理学观察。
结果与结论:①细胞移植组心脏存活时间显著长于空白对照组(P < 0.05);②两组血清白细胞介素2水平差异无显著性意义(P > 0.05),细胞移植组血清白细胞介素10水平显著高于空白对照组(P < 0.05);③细胞移植组CD4+、CD4+/CD8+、CD4+CD25high、CD4+CD25high Foxp3+ T细胞占总淋巴细胞的比例均显著高于空白对照组(P < 0.05),CD8+ T细胞占总淋巴细胞的比例显著低于空白对照组(P < 0.05);④细胞移植组心肌组织中有少量淋巴细胞浸润,心肌间质可观察到轻微出血和水肿,较空白对照组炎性反应程度较轻;⑤结果表明,对心脏移植大鼠实施骨髓间充质干细胞治疗可以有效减轻排斥反应。

 

 

关键词: 干细胞, 骨髓间充质干细胞, 心脏移植, 器官移植, 免疫功能, 动物实验

Abstract:

BACKGROUND: Heart transplantation is an effective method for treatment of end-stage heart failure, but immune rejection that seriously impact therapeutic effacicy is easy to occur after transplantation.
OBJECTIVE: To investigate the regulatory effect of bone marrow mesenchymal stem cells on the immune function of rats undergoiong heart transplantation.
METHODS: Twenty Lewis rats were enrolled as donors, and 20 Wistar rats as recipients. Heart transplantation models were established in the Wistar rats. These 20 model rats were randomized into cell transplantation and control group with 10 rats in each group. Forty-eight hours after heart transplantation, rats in the cell transplantation group were given bone marrow mesenchymal stem cell suspension
(1 mL, 2×108 cells/L) via the tail vein, while rats in the control group were given normal saline in the same dose. Then, the expression levels of serum interleukin-2, interleukin-10 and percentage of CD4+, CD8+, CD4+/CD8+, CD4+CD25high, CD4+CD25high Foxp3+ T cells in the venous blood were detected in the two groups at 7 days after cell transplantation. Additionally, rat myocardial tissues were taken and observed pathologically.
RESULTS AND CONCLUSION: The survival time of the cell transplantation group was significantly longer than that of the control group (P < 0.05). The expression level of interleukin-2 showed no significant difference between the two groups (P > 0.05), but the level of interleukin-10 in the cell transplantation group was significantly higher than that in the control group (P < 0.05). Compared with the control group, the percentage of CD4+/CD8+, CD4+CD25high, CD4+CD25high Foxp3+ and CD4+ T cells was significantly higher, and the percentage of CD8+ T cells was significantly lower in the cell transplantation group (P < 0.05). Histopathological findings showed that there were a small amount of infiltrated lymphocytes in the cell transplantation group with the presence of slight bleeding and edema, and these inflammatory reactions were milder than those in the control group. These findings indicate that bone marrow mesenchymal stem cell transplantation can effectively reduce the rejection in rats undergoing heart transplantation.

 

 

Key words: Heart Transplantation, Bone Marrow, Mesenchymal Stem Cell Transplantation, Immunomodulation, Tissue Engineering

中图分类号: